Inbentus, the engineering, consulting and medical technology company, continues with the success of its Crowdcube round. The startup opened this financing round with the goal of raising 200,000 euros, a figure it obtained in just eight days. For Rafael Valderde, CEO of the startup, this initial support "has allowed them to take action much faster than expected".
For this reason, and in view of the interest of investors, Inbentus continues to seek support. Interested parties can join the operation, which will close on February 16, through the website. To date, more than 400 investors have already joined the company.
Inbentus aims to use the funds to boost sales and complete the licensing of its existing ventilator; launch local campaigns in the target countries; and develop a new high-performance ventilator product. Valderde specifies that "the extra funds being raised right now will be focused mainly on accelerating development work on a new ventilator and opening a branch office in Paraguay to sell the emergency ventilator before the third wave arrives in that country, expected in April/May."
Inbentus was born with a multidisciplinary purpose thanks to the initiative of a group of professionals and leading companies in different sectors. They have joined forces and knowledge to provide solutions through the creation of innovative products. Especially important when designing and manufacturing such necessary products as the SAV-19, an automatic mechanical ventilator to cope with the Covid-19 and the global health crisis.
Beyond COVID, thousands of people die every day for lack of medical ventilators. These highly reliable devices are inaccessible to emerging markets due to their cost. COVID19 has undoubtedly exacerbated this situation. That is why Inbentus wants to make ventilators accessible to less affluent populations.
They were created for this purpose at the beginning of 2020. International studies indicate that respiratory pathologies will be a major global problem over the next 20 years; in fact, they are already the third leading cause of death worldwide according to the World Health Organization. Some of the reasons:
- The increase of the world population by almost 30%.
- Increased life expectancy.
By 2027, more than €12 billion is expected to be spent on respiratory medical technology, which has sustained annual growth of 16%.
Located in the Region of Murcia, the company maintains a clear commitment to the development of new technologies, betting on human capital as the engine of its growth. With this in mind, it continually explores new professional synergies for the expansion of production and the excellence of each project.
Rafael Valverde therefore encourages investors to join this project: "We have already covered the capital increase required for our conservative planning. And now, with your support, we will be able to shorten the time and make the dream become a reality sooner".
Reference: Inbentus will keep its Crowcube round open until February 17 (elreferente.es)
